Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Titel:
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Auteur:
Grande, Enrique Arranz, José Á De Santis, Maria Bamias, Aristotelis Kikuchi, Eiji del Muro, Xavier Garcia Park, Se Hoon De Giorgi, Ugo Alekseev, Boris Mencinger, Marina Izumi, Kouji Schutz, Fabio A Puente, Javier Li, Jian-Ri O'Donnell, Peter H Kalebasty, Arash Rezazadeh Ye, Dingwei Mariathasan, Sanjeev Bene-Tchaleu, FabioIa Bernhard, Sandrine Lee, Chooi Davis, Ian D Galsky, Matthew D